<div id="readability-page-1"><div> <h2>Key Points</h2><ul><li>Tilray Brands believes it's in a great position to take advantage of opportunities in a regulated medical marijuana market in the U.S.</li><li>Any effort to legalize marijuana in the U.S. could take years, and there's no indication that it's even on the radar of lawmakers.</li><li>10 stocks we like better than Tilray Brands ›</li></ul>The U.S. government recently rescheduled medical marijuana from a Schedule I substance to Schedule III, which is great news for the industry and marks a milestone. It's an acknowledgment that there are valid medical uses for marijuana, and many cannabis companies in the U.S. will benefit as a result of that.Tilray Brands (NASDAQ: TLRY) is a Canadian-based cannabis producer, and while there may be optimism around it potentially entering the U.S. marijuana market, here's why you shouldn't count on that happening anytime soon.Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an &#34;Indispensable Monopoly&#34; providing the critical technology Nvidia and Intel both need. Continue »<img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2NzMwMy9hLWNvdXBsZS11c2luZy1hLWxhcHRvcC1hbmQtcmV2aWV3aW5nLWRvY3VtZW50cy5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="700" height="466" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2NzMwMy9hLWNvdXBsZS11c2luZy1hLWxhcHRvcC1hbmQtcmV2aWV3aW5nLWRvY3VtZW50cy5qcGcmdz03MDA"/>Image source: Getty Images. <h2>Rescheduling is not legalization</h2>The most important thing for cannabis investors to remember is that rescheduling marijuana is not the same thing as legalization. With rescheduling, it'll be easier to research marijuana in the U.S., but by no means is the border open for Canadian producers to move cannabis products south. Marijuana remains a controlled substance and is federally illegal. While rescheduling has taken place for medically licensed marijuana, recreational products haven't been rescheduled yet, and while it may seem that the industry is moving toward legalization, there is nothing to suggest that will happen anytime soon.Tilray Brands, however, jumped at the opportunity to remind investors that it's &#34;positioned for U.S. expansion&#34; in a recent press release, in which it called the move &#34;a defining inflection point.&#34; While Tilray is definitely in a good position to take advantage if the opportunity arises to enter the U.S. pot market (whether for recreational or medicinal products), that doesn't mean a big move like that is coming soon. Even if the Trump administration moved forward with legalization efforts or broader reform, the process alone could take years. Investors shouldn't forget that it was back in October 2022 when then-President Joe Biden first asked the U.S. Department of Health and Human Services and Drug Enforcement Administration to review marijuana scheduling. Government reform can take a considerable amount of time.<h2>Investing based on hopes of government reform hasn't played out well for investors</h2>For years, cannabis investors have been holding onto pot stocks in the hopes that legalization in the U.S. might be coming soon. In the end, it has simply resulted in some significant losses. The last time Tilray Brands' stock generated a positive annual return for investors was back in 2018, when it soared 215% -- when Canada legalized marijuana. It's been downhill ever since, in what's been an epic example of &#34;buy the rumor, sell the news.&#34;Tilray Brands stock has made for a disappointing investment to own for several years, and there's little reason to expect things to change anytime soon. Legalization in the U.S. is the big carrot that draws in investors, but it's not on the horizon, and even if it were, it could still be years away from being a possibility. The safest option is to take a wait-and-see approach with Tilray, as it's far too risky a stock to hold.<h2>Should you buy stock in Tilray Brands right now?</h2> Before you buy stock in Tilray Brands, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tilray Brands wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $496,473!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,605!* Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 202% for the S&amp;P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 2, 2026. David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

TLRY

YOLO

MSOS

Tilray Brands, a Canadian cannabis producer, is optimistic about entering the U.S. marijuana market following the U.S. government's rescheduling of medical marijuana to Schedule III. However, this rescheduling does not equate to legalization, and marijuana remains federally illegal in the U.S. Despite Tilray's claims of being positioned for U.S. expansion, significant government reform could take years. Investors have faced losses in cannabis stocks, and the outlook for Tilray remains uncertain, suggesting a cautious approach is advisable.

nasdaq

Tilray Brands

AdvisorShares Pure Cannabis ETF

AdvisorShares Pure US Cannabis ETF

NVIDIA

Intel

Netflix

Nasdaq

S&P 500

NVIDIA Corporation

Tilray Brands to Expand Into the U.S. Marijuana Market? Why You Shouldn't Count on That Anytime Soon